Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

Benzinga Newsdesk www.benzinga.com Positive 74.2%

Neg 0% Neu 0% Pos 74.2%

Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.